Enovis Corporation/$ENOV
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Enovis Corporation
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
- Ticker
- $ENOV
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 7,802
- Headquarters
- Lewisville, United States
- Website
- www.enovis.com
ENOV Metrics
BasicAdvanced
$1.2B
-
-$19.22
1.48
-
Price and volume
Market cap
$1.2B
Beta
1.48
52-week high
$34.28
52-week low
$16.70
Average daily volume
1.5M
Financial strength
Current ratio
1.985
Quick ratio
0.742
Long term debt to equity
0.883
Total debt to equity
0.926
Interest coverage (TTM)
1.07%
Profitability
EBITDA (TTM)
379.792
Gross margin (TTM)
61.31%
Net profit margin (TTM)
-47.97%
Operating margin (TTM)
3.66%
Effective tax rate (TTM)
-2.88%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
1.19%
Return on equity (TTM)
-54.14%
Valuation
Price to revenue (TTM)
0.528
Price to book
0.83
Price to tangible book (TTM)
-3.19
Price to free cash flow (TTM)
19.052
Free cash flow yield (TTM)
5.25%
Free cash flow per share (TTM)
1.111
Growth
Revenue change (TTM)
4.89%
Earnings per share change (TTM)
30.94%
3-year revenue growth (CAGR)
12.17%
10-year revenue growth (CAGR)
-4.49%
3-year earnings per share growth (CAGR)
95.79%
10-year earnings per share growth (CAGR)
20.39%
What the Analysts think about ENOV
Analyst ratings (Buy, Hold, Sell) for Enovis Corporation stock.
Analyst projections of the future price of Enovis Corporation stock.
Bulls say / Bears say
Reconstructive is gaining momentum: first-half organic sales grew 5.9%, with strength in US hips and knees and international markets. New products such as Nebula and ARVIS could help sustain share gains. (Enovis, SquawkNews)
Margins and cash generation are improving, and Enovis reaffirmed its 2026 outlook for 4–6% organic growth and at least 25% free-cash-flow conversion. Adjusted EBITDA margin reached 17.9% in Q2, while first-half free cash flow turned slightly positive. (Enovis, SquawkNews)
FDA clearance for Spinalogic’s expanded use after certain cervical fusion procedures gives Enovis another route to grow its bone-stimulation business. The added indication broadens the product’s potential use beyond lumbar fusion. (Enovis)
The proposed eCential Robotics deal adds investment and financing risk: Enovis plans to fund about €176 million of cash consideration partly with revolver borrowings, and expects a net 100-basis-point adjusted EBITDA margin headwind in 2027. The company reported $1.28 billion of debt at the end of Q2. (Enovis, SEC)
Management expects a more difficult third quarter as Western European conditions and Middle East disruption weigh on business, while inflation and tariffs add cost pressure. It said these factors are challenging to pass on without risking sales. (Investing.com)
Despite positive adjusted results, Enovis remained loss-making under GAAP: it reported a $9.5 million net loss for the first half of 2026. That leaves less evidence so far that operating improvements have translated into bottom-line profitability. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 25 Oct 2026.
ENOV Financial Performance
Revenues and expenses
ENOV Earnings Performance
Company profitability
Upcoming events
No upcoming events
ENOV News
AllArticlesVideos
Funds containing ENOV
AllUSDEURGBP
Fund name | Fund size | $ENOV weighting |
|---|---|---|
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.07% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.07% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.04% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.04% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.